San Francisco, California 94115


RATIONALE: Diagnostic procedures, such as contrast-enhanced MRI, may help find and diagnose ductal carcinoma in situ. PURPOSE: This randomized clinical trial is studying contrast-enhanced MRI in women with ductal breast carcinoma in situ and in healthy volunteers.

Study summary:

OBJECTIVES: - To compare ductal carcinoma in situ (DCIS)-optimized MRI with standard clinical MRI, in terms of conspicuity of DCIS lesion, agreement of disease extent with biopsy, and overall image quality (i.e., artifact level, uniformity of fat suppression, contrast to noise ratio and signal to noise ratio), in women with DCIS of the breast. - To compare two DCIS-optimized MRIs for variability in enhancement levels for DCIS. - To examine the effect of the menstrual cycle on the variability of background enhancement levels in healthy volunteers. OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 arms. - Arm I: Patients undergo standard clinical contrast-enhanced MRI over approximately 30-45 minutes. No more than 3 days later, patients undergo ductal carcinoma in situ (DCIS)-optimized contrast-enhanced MRI. - Arm II: Patients undergo DCIS-optimized contrast-enhanced MRI over approximately 30-45 minutes. No more than 3 days later, patients undergo a second DCIS-optimized contrast-enhanced MRI. Healthy volunteers undergo DCIS-optimized contrast-enhanced MRI as in arm II.


DISEASE CHARACTERISTICS: - Meets 1 of the following criteria: - Patient at the University of California, San Francisco Breast Care Center meeting the following criteria: - Biopsy proven ductal carcinoma in situ (DCIS) of the breast - Has undergone mammography within the past 60 days - Healthy volunteer - No prior breast disease PATIENT CHARACTERISTICS: - Not pregnant or nursing (or stopped nursing within the past 3 months) - Negative pregnancy test - No contraindication to MRI (e.g., implanted pacemaker, implanted ferromagnetic device, ferromagnetic aneurysm clip, severe claustrophobia, ocular metal fragments, or shrapnel injury) PRIOR CONCURRENT THERAPY: - More than 2 years since prior surgery to the ipsilateral breast (patient) - No prior radiotherapy to the ipsilateral breast (patient) - No prior cytotoxic regimens (patient)



Primary Contact:

Principal Investigator
Nola M. Hylton, PhD
University of California, San Francisco

Backup Contact:


Location Contact:

San Francisco, California 94115
United States

Clinical Trials Office - UCSF Helen Diller Family Comprehensi
Phone: 877-827-3222

Site Status: Recruiting

Data Source:

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.